Technology
Health
Biotechnology

Rocket Pharmaceuticals

$12.25
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.50 (-3.92%) Today
$0.00 (0.00%) As of 4:00 PM EDT after-hours

Why Robinhood?

You can buy or sell RCKT and other stocks, options, ETFs, and crypto commission-free!

About RCKT

Rocket Pharmaceuticals, Inc. Common Stock, also called Rocket Pharmaceuticals, is a clinical-stage biotechnology company, which engages in the development of first-in-class gene therapy treatment options for rare and devastating pediatric diseases. Read More Its multi-platform development approach applies the lentiviral vector (LVV) and adeno-associated viral vector (AAV) gene therapy platforms. The firm's clinical program is a LVV-based gene therapy for the treatment of Fanconi Anemia (FA), a difficult to treat genetic disease that leads to bone marrow failure and potentially cancer. The company was founded in 1999 and is headquartered in New York, NY.

Employees
39
Headquarters
New York, New York
Founded
Market Cap
575.21M
Price-Earnings Ratio
Dividend Yield
0.00
Average Volume
652.03K
High Today
$12.84
Low Today
$12.20
Open Price
$12.84
Volume
567.73K
52 Week High
$25.96
52 Week Low
$10.75

Collections

Technology
Health
Biotechnology
Therapy
Medical
Cancer Prevention
2015 IPO
US

RCKT Earnings

-$0.66
-$0.56
-$0.47
-$0.37
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Q2 2019
Estimated
Actual
Expected Aug 7, Pre-Market
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.